Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 3/20 | 0.46 |
| ▸ | GRB2 | P62993 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.41 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | RAMP3 | O60896 | 5/20 | 0.41 |
| ▸ | CALCR | P30988 | 5/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30349254 | 0.88 | RAMP3 (0.52) | F2NMUR2NMUR1RAMP3CALCR | |
| SCHEMBL30185034 | 0.87 | CAPN1 (0.43) | CAPN1GRB2 | |
| SCHEMBL29512229 | 0.86 | BDKRB2 (0.44) | CAPN1NMUR2NMUR1OPRM1OPRD1 | |
| SCHEMBL30185039 | 0.86 | CAPN1 (0.48) | CAPN1GRB2F2OPRM1OPRD1 | |
| SCHEMBL30883252 | 0.86 | CAPN1 (0.46) | CAPN1RAMP3CALCR | |
| SCHEMBL7857993 | 0.83 | CAPN1 (0.46) | CAPN1GRB2 | |
| SCHEMBL29800494 | 0.83 | OPRM1 (0.44) | NMUR2NMUR1OPRM1OPRD1RAMP3 | |
| SCHEMBL31126309 | 0.83 | CAPN1 (0.45) | CAPN1GRB2F2OPRM1OPRD1 | |
| SCHEMBL29617972 | 0.83 | ITGB1 (0.45) | CAPN1GRB2F2OPRM1OPRD1 | |
| SCHEMBL29617974 | 0.83 | ITGB1 (0.45) | CAPN1GRB2F2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4163289-B1 | INHIBITOR POLYPEPTIDE COMPOUND TARGETING FIBRONECTIN-DERIVED PEPTIDES AND USE THEREOF | SHENZHEN TURIER BIOTECH CO LTD (CN) | 2026-02-18 | — | — | EP | claimed |
| US-20240336653-A1 | PEPTIDE COMPOUND TARGETING ELASTIN-DERIVED PEPTIDES AND USE THEREOF | SHENZHEN TURIER BIOTECH CO., LTD. (CN) | 2024-10-10 | — | — | US | claimed |
| CN-117106029-A | Inhibitor polypeptide compound targeting fibronectin derived peptide and application thereof | 深圳市图微安创科技开发有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-111704653-B | Inhibitor polypeptide compound targeting fibronectin derived peptide and application thereof | 深圳市图微安创科技开发有限公司 | 2023-10-03 | — | — | CN | claimed |
| WO-2022178841-A1 | COMBINATION OF ADIPONECTIN RECEPTOR AGONIST AND ELASTIN RECEPTOR INHIBITOR FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | 深圳市图微安创科技开发有限公司 | 2022-09-01 | — | — | WO | claimed |
| EP-4163289-B1 | INHIBITOR POLYPEPTIDE COMPOUND TARGETING FIBRONECTIN-DERIVED PEPTIDES AND USE THEREOF | SHENZHEN TURIER BIOTECH CO LTD (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20240336653-A1 | PEPTIDE COMPOUND TARGETING ELASTIN-DERIVED PEPTIDES AND USE THEREOF | SHENZHEN TURIER BIOTECH CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| US-20240336653-A1 | PEPTIDE COMPOUND TARGETING ELASTIN-DERIVED PEPTIDES AND USE THEREOF | SHENZHEN TURIER BIOTECH CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| CN-117106029-A | Inhibitor polypeptide compound targeting fibronectin derived peptide and application thereof | 深圳市图微安创科技开发有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117106029-A | Inhibitor polypeptide compound targeting fibronectin derived peptide and application thereof | 深圳市图微安创科技开发有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-111704653-B | Inhibitor polypeptide compound targeting fibronectin derived peptide and application thereof | 深圳市图微安创科技开发有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-111704653-B | Inhibitor polypeptide compound targeting fibronectin derived peptide and application thereof | 深圳市图微安创科技开发有限公司 | 2023-10-03 | — | — | CN | disclosed |
| JP-2023527483-A | — | シェンチェン チュリエ バイオテック カンパニー リミテッド | 2023-06-28 | — | — | JP | disclosed |
| WO-2022178841-A1 | COMBINATION OF ADIPONECTIN RECEPTOR AGONIST AND ELASTIN RECEPTOR INHIBITOR FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | 深圳市图微安创科技开发有限公司 | 2022-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336653-A1 | PEPTIDE COMPOUND TARGETING ELASTIN-DERIVED PEPTIDES AND USE THEREOF | XPNPEP2, XPNPEP1, PEX14 | CAPN1 3721/4885GRB2 3553/4885F2 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.